GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Gross Profit

Zeo ScientifiX (Zeo ScientifiX) Gross Profit : $998 Mil (TTM As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Gross Profit?

Zeo ScientifiX's gross profit for the three months ended in Jan. 2024 was $995 Mil. Zeo ScientifiX's gross profit for the trailing twelve months (TTM) ended in Jan. 2024 was $998 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Zeo ScientifiX's gross profit for the three months ended in Jan. 2024 was $995 Mil. Zeo ScientifiX's Revenue for the three months ended in Jan. 2024 was $1,154 Mil. Therefore, Zeo ScientifiX's Gross Margin % for the quarter that ended in Jan. 2024 was 86.22%.

Zeo ScientifiX had a gross margin of 86.22% for the quarter that ended in Jan. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Zeo ScientifiX was 90.23%. The lowest was 48.65%. And the median was 82.31%.


Zeo ScientifiX Gross Profit Historical Data

The historical data trend for Zeo ScientifiX's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Gross Profit Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 2.66 5.05 5.74 4.05

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 966.00 0.74 1.06 1.29 995.00

Competitive Comparison of Zeo ScientifiX's Gross Profit

For the Biotechnology subindustry, Zeo ScientifiX's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Gross Profit distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Gross Profit falls into.



Zeo ScientifiX Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Zeo ScientifiX's Gross Profit for the fiscal year that ended in Oct. 2023 is calculated as

Gross Profit (A: Oct. 2023 )=Revenue - Cost of Goods Sold
=4.558 - 0.507
=4

Zeo ScientifiX's Gross Profit for the quarter that ended in Jan. 2024 is calculated as

Gross Profit (Q: Jan. 2024 )=Revenue - Cost of Goods Sold
=1154 - 159
=995

Gross Profit for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $998 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Zeo ScientifiX's Gross Margin % for the quarter that ended in Jan. 2024 is calculated as

Gross Margin % (Q: Jan. 2024 )=Gross Profit (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=995 / 1154
=86.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Zeo ScientifiX  (OTCPK:ZEOX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Zeo ScientifiX had a gross margin of 86.22% for the quarter that ended in Jan. 2024 => Durable competitive advantage


Zeo ScientifiX Gross Profit Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140